FAQ/Help |
Calendar |
Search |
Today's Posts |
10-03-2018, 06:03 PM | #1 | ||
|
|||
Senior Member
|
Heinzel et al. report [1]:
"Based on claims data of 3.7 million statutory insurance members in Germany in 2015 ... Prevalence of (co-)occurring diseases, mortality, and healthcare measures in PD cases and matched controls were compared. In 2015, 21,714 prevalent PD cases (standardized prevalence: 511.4/100,000 persons) and 3,541 incident PD cases (standardized incidence: 84.1/100,000 persons) were identified. Prevalence of several (co-)occurring diseases/complications, e.g., dementia (PD/controls: 39/13%), depression (45/22%), bladder dysfunction (46/22%), and diabetes (35/31%), as well as mortality (10.7/5.8%) differed between PD cases and controls." Reference: [1] "Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany?" Heinzel S., et al. Front Neurol, June 2018 Frontiers | Do We Need to Rethink the Epidemiology and Healthcare Utilization of Parkinson's Disease in Germany? | Neurology John
__________________
Born 1955. Diagnosed PD 2005. Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||
Temporal epidemiology | Parkinson's Disease | |||
Epidemiology of Young Onset PD in US | Parkinson's Disease | |||
Meteorological epidemiology | Parkinson's Disease | |||
Why is there so little focus on epidemiology? | Parkinson's Disease |